FDA approves Guardant Health's Shield blood test for colorectal cancer screening in adults aged 45+.
FDA approves Guardant Health's Shield blood test as a primary screening option for colorectal cancer in adults aged 45+ with average risk. The non-invasive test offers an alternative to colonoscopies and stool tests, increasing screening rates and detecting cancers at an early, treatable stage. This is the first blood test to receive such approval and meets requirements for Medicare coverage.
July 29, 2024
6 Articles